This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): linezolid
Description: Linezolid is a synthetic antibiotic belongingto a new class of antimicrobials called the oxazolidinones.Linezolid disrupts bacterialgrowth by inhibiting the initiation process inprotein synthesis. This site of inhibitionoccurs earlier in the initiation process thanother protein synthesis inhibitors (e.g., chlo-ramphenicol [Chloromycetin],clindamycin[Cleocin], aminoglycosides, and macrolides)that interfere with the elongation process.Because the site of inhibition is unique to linezolid,cross-resistance to other protein synthesisinhibitors has not yet been reported.Linezolid may also inhibit virulence factorexpression and decrease toxin production ingram-positive pathogens.
Linezolid exhibits good activity against methicillin-sensitive and -resistant S. aureus, streptococci (including multidrug resistant S. pneumoniae), enterococci (including VRE) and Nocardia; moderate activity against certain atypicals; and poor activity against Gram-(-) bacteria and anaerobes.
Additional information available to subscribers only: